David J. Delgado, PhD, MPH
Philadelphia, PA 19107
(215) 923-7583 fax
PhD, University of California, Los Angeles
MPH, Columbia University
BA, Harvard University
Associate Professor, Jefferson College of Population Health
Program Director, Applied Health Economics & Outcomes Research, Jefferson College of Population Health
Research & Practice Interests
Cancer Health Disparities
Applied Health Economics and Outcomes Research
Economic & Outcomes Analyses
Integrative Research Seminar
Health Research Methods
Applied Health Economics & Outcomes Capstone Seminar & Project
Public Health Capstone Seminar & Project
Dr. David Delgado brings a blended perspective to the table. He has a BA in Sociology from Harvard University, a MPH in Health Planning and Administration from Columbia University and a PhD in Health Services Research and Epidemiology from the University of California, Los Angeles.
Dr. Delgado helped establish a federally qualified health center where he developed a breast and cervical cancer prevention intervention and a tobacco control program. He was a postdoctoral cancer control fellow at the University of Southern California where he published research examining the association of socio-economic status and race/ethnicity on breast cancer survival and mapped the prevalence of late-staged breast cancer diagnosis in Los Angeles. He worked at Amgen for 9 years, where he did financial reporting and worked on teams to describe patterns of care and develop risk models for chemotherapy-related complications.
At West Chester University, Dr. Delgado taught undergraduate and graduate students courses in healthcare finance, evidence-based medicine, research methods, health advocacy, health law, wellness and transcultural health. At the Jefferson College of Population Health he directed the PhD program for two years, currently directs the Applied Health Economics & Outcomes Research (AHEOR) programs and mentors several HEOR postdoctoral Fellows.
Dr. Delgado's research explores disparities in cancer stage, treatment and outcomes using the National Cancer Institute’s SEER database.
Most Recent Peer-Reviewed Publications
- Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States)
- Severe neutropenia in CHOP occurs most frequently in cycle 1: A predictive model
- Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's lymphoma cases during first-course chemotherapy
- Risk and Timing of Hospitalization for Febrile Neutropenia in Patients Receiving CHOP, CHOP-R, or CNOP Chemotherapy for Intermediate-Grade Non-Hodgkin Lymphoma
- Risk of febrile neutropenia-among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy
- Factors Associated With Early Termination of CHOP Therapy and the Impact on Survival among Patients with Chemosensitive Intermediate-Grade Non-Hodgkin's Lymphoma
- Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy.
- Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma
- Patterns of chemotherapy administration in patients with intermediate-grade non-hodgkin's lymphoma
- The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-hodgkin’s lymphoma receiving initial CHOP chemotherapy: A risk factor analysis